What is chronic bronchitis?
Bronchitis is an inflammation of the lining of the bronchial tubes. These tubes connect the windpipe with the lungs. When the bronchi are inflamed and/or infected, less air is able to flow to and from the lungs and a heavy mucus or phlegm is coughed up. This is bronchitis. Many people suffer a brief attack of acute bronchitis with cough and mucus production when they have severe colds. Acute bronchitis is usually not associated with fever.
Chronic bronchitis is defined by the presence of a mucus-producing cough most days of the month, three months of a year for two successive years without other underlying disease to explain the cough. It may precede or accompany pulmonary emphysema or COPD.
COPD Clinical Research Trials
ROF-MD-07: A 52-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Roflumilast 500 ?g on Exacerbation Rate in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Treated With a Fixed-Dose Combination of Long-Acting Beta Agonist and Inhaled Corticosteroid (LABA/ICS).
Purpose: To demonstrate the additional benefit of roflumilast when added on to fixed-dose combination (FDC) LABA/ICS in the reduction of exacerbations in subjects with severe to very severe COPD. Participation could last up to 58 weeks.
Patient Flyer (PDF)
ASCENT (LAS-MD-45): Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase IV Study to Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and COPD Exacerbations in Patients With Moderate to Very Severe COPD (ASCENT COPD).
Purpose: The objectives of this study are to assess the safety of Aclidinium bromide on major adverse cardiovascular events (MACE), to assess the overall safety of Aclidinium bromide and to assess whether Aclidinium bromide reduces moderate or severe COPD exacerbations. Participation could last up to 36 months.
Pulmonary Function Testing (PFT)
For All Studies:
Qualified participants will receive study-related care, study-related exams and study-related medication at no cost. Participants may be compensated for their time and travel.
If you are interested in participating in a study or would like more information, register now or contact The Lung Research Center at 314-439-LUNG (5864) or email: firstname.lastname@example.org.